User menu

Cardiovascular side effects of cancer therapies : a position statement from the Heart Failure Association of the European Society of Cardiology.

Bibliographic reference Eschenhagen, Thomas ; Force, Thomas ; Ewer, Michael S. ; de Keulenaer, Gilles W. ; Suter, Thomas M. ; et. al. Cardiovascular side effects of cancer therapies : a position statement from the Heart Failure Association of the European Society of Cardiology.. In: European journal of heart failure, Vol. 13, no. 1, p. 1-10 (2011)
Permanent URL http://hdl.handle.net/2078.1/82298
  1. Jemal A., Siegel R., Xu J., Ward E., Cancer Statistics, 2010, 10.3322/caac.20073
  2. American Cancer Society 2010
  3. National Cancer Institute 2009
  4. Gianni Luca, Herman Eugene H., Lipshultz Steven E., Minotti Giorgio, Sarvazyan Narine, Sawyer Douglas B., Anthracycline Cardiotoxicity: From Bench to Bedside, 10.1200/jco.2007.14.9401
  5. Telli Melinda L., Hunt Sharon A., Carlson Robert W., Guardino Alice E., Trastuzumab-Related Cardiotoxicity: Calling Into Question the Concept of Reversibility, 10.1200/jco.2007.11.0106
  6. VON HOFF DANIEL D., Risk Factors for Doxorubicin-lnduced Congestive Heart Failure, 10.7326/0003-4819-91-5-710
  7. Swain Sandra M., Whaley Fredrick S., Ewer Michael S., Congestive heart failure in patients treated with doxorubicin : A retrospective analysis of three trials, 10.1002/cncr.11407
  8. Pinder Mary C., Duan Zhigang, Goodwin James S., Hortobagyi Gabriel N., Giordano Sharon H., Congestive Heart Failure in Older Women Treated With Adjuvant Anthracycline Chemotherapy for Breast Cancer, 10.1200/jco.2006.10.4976
  9. Mann D. L., Mechanisms and Models in Heart Failure: The Biomechanical Model and Beyond, 10.1161/circulationaha.104.500546
  10. Ewer Michael S., Lenihan Daniel J., Left Ventricular Ejection Fraction and Cardiotoxicity: Is Our Ear Really to the Ground?, 10.1200/jco.2007.14.8742
  11. Lipshultz Steven E., Rifai Nader, Dalton Virginia M., Levy Donna E., Silverman Lewis B., Lipsitz Stuart R., Colan Steven D., Asselin Barbara L., Barr Ronald D., Clavell Luis A., Hurwitz Craig A., Moghrabi Albert, Samson Yvan, Schorin Marshall A., Gelber Richard D., Sallan Stephen E., The Effect of Dexrazoxane on Myocardial Injury in Doxorubicin-Treated Children with Acute Lymphoblastic Leukemia, 10.1056/nejmoa035153
  12. Swain, J Clin Oncol, 15, 1318 (1997)
  13. Swain, J Clin Oncol, 15, 1333 (1997)
  14. Ewer Michael S., Martin Francis J., Henderson I. Craig, Shapiro Charles L., Benjamin Robert S., Gabizon Alberto A., Cardiac safety of liposomal anthracyclines, 10.1053/j.seminoncol.2004.08.006
  15. Wojnowski L., NAD(P)H Oxidase and Multidrug Resistance Protein Genetic Polymorphisms Are Associated With Doxorubicin-Induced Cardiotoxicity, 10.1161/circulationaha.105.576850
  16. Bristow, Cancer Treat Rep, 62, 873 (1978)
  17. Bergmann Olaf, Bhardwaj Ratan D., Bernard Samuel, Zdunek Sofia, Barnabé-Heider Fanie, Walsh Stuart, Zupicich Joel, Alkass Kanar, Buchholz Bruce A., Druid Henrik, Jovinge Stefan, Frisén Jonas, Evidence for Cardiomyocyte Renewal in Humans, 10.1126/science.1164680
  18. Lipshultz Steven E., Lipsitz Stuart R., Sallan Stephen E., Dalton Virginia M., Mone Suzanne M., Gelber Richard D., Colan Steven D., Chronic Progressive Cardiac Dysfunction Years After Doxorubicin Therapy for Childhood Acute Lymphoblastic Leukemia, 10.1200/jco.2005.12.121
  19. Ross Jeffrey S., Fletcher Jonathan A., The HER‐2/neuOncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy, 10.1002/stem.160413
  20. Seshadri, J Clin Oncol, 11, 1936 (1993)
  21. Junttila Teemu T., Akita Robert W., Parsons Kathryn, Fields Carter, Lewis Phillips Gail D., Friedman Lori S., Sampath Deepak, Sliwkowski Mark X., Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941, 10.1016/j.ccr.2009.03.020
  22. De Keulenaer G. W., Doggen K., Lemmens K., The Vulnerability of the Heart As a Pluricellular Paracrine Organ: Lessons From Unexpected Triggers of Heart Failure in Targeted ErbB2 Anticancer Therapy, 10.1161/circresaha.109.205906
  23. Crone Steven A., Zhao You-Yang, Fan Lian, Gu Yusu, Minamisawa Susumu, Liu Yang, Peterson Kirk L., Chen Ju, Kahn Ronald, Condorelli Gianluigi, Jr John Ross, Chien Kenneth R., Lee Kuo-Fen, ErbB2 is essential in the prevention of dilated cardiomyopathy, 10.1038/nm0502-459
  24. Negro A., Brar B. K., Gu Y., Peterson K. L., Vale W., Lee K.-F., erbB2 is required for G protein-coupled receptor signaling in the heart, 10.1073/pnas.0607499103
  25. Ozcelik C., Erdmann B., Pilz B., Wettschureck N., Britsch S., Hubner N., Chien K. R., Birchmeier C., Garratt A. N., Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy, 10.1073/pnas.122249299
  26. Romond Edward H., Perez Edith A., Bryant John, Suman Vera J., Geyer Charles E., Davidson Nancy E., Tan-Chiu Elizabeth, Martino Silvana, Paik Soonmyung, Kaufman Peter A., Swain Sandra M., Pisansky Thomas M., Fehrenbacher Louis, Kutteh Leila A., Vogel Victor G., Visscher Daniel W., Yothers Greg, Jenkins Robert B., Brown Ann M., Dakhil Shaker R., Mamounas Eleftherios P., Lingle Wilma L., Klein Pamela M., Ingle James N., Wolmark Norman, Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer, 10.1056/nejmoa052122
  27. Smith Ian, Procter Marion, Gelber Richard D, Guillaume Sébastien, Feyereislova Andrea, Dowsett Mitch, Goldhirsch Aron, Untch Michael, Mariani Gabriella, Baselga Jose, Kaufmann Manfred, Cameron David, Bell Richard, Bergh Jonas, Coleman Robert, Wardley Andrew, Harbeck Nadia, Lopez Roberto I, Mallmann Peter, Gelmon Karen, Wilcken Nicholas, Wist Erik, Sánchez Rovira Pedro, Piccart-Gebhart Martine J, 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial, 10.1016/s0140-6736(07)60028-2
  28. Piccart-Gebhart Martine J., Procter Marion, Leyland-Jones Brian, Goldhirsch Aron, Untch Michael, Smith Ian, Gianni Luca, Baselga Jose, Bell Richard, Jackisch Christian, Cameron David, Dowsett Mitch, Barrios Carlos H., Steger Günther, Huang Chiun-Shen, Andersson Michael, Inbar Moshe, Lichinitser Mikhail, Láng István, Nitz Ulrike, Iwata Hiroji, Thomssen Christoph, Lohrisch Caroline, Suter Thomas M., Rüschoff Josef, Sütő Tamás, Greatorex Victoria, Ward Carol, Straehle Carolyn, McFadden Eleanor, Dolci M. Stella, Gelber Richard D., Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer, 10.1056/nejmoa052306
  29. Suter T.M, Cook-Bruns N, Barton C, Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer, 10.1016/j.breast.2003.09.002
  30. Sawyer D. B., Modulation of Anthracycline-Induced Myofibrillar Disarray in Rat Ventricular Myocytes by Neuregulin-1beta and Anti-erbB2: Potential Mechanism for Trastuzumab-Induced Cardiotoxicity, 10.1161/01.cir.0000013839.41224.1c
  31. Ewer Michael S., Vooletich Mary T., Durand Jean-Bernard, Woods Myrshia L., Davis Joseph R., Valero Vicente, Lenihan Daniel J., Reversibility of Trastuzumab-Related Cardiotoxicity: New Insights Based on Clinical Course and Response to Medical Treatment, 10.1200/jco.2005.13.300
  32. Ewer Michael S., Lippman Scott M., Type II Chemotherapy-Related Cardiac Dysfunction: Time to Recognize a New Entity, 10.1200/jco.2005.05.827
  33. de Korte M.A., de Vries E.G.E., Lub-de Hooge M.N., Jager P.L., Gietema J.A., van der Graaf W.T.A., Sluiter W.J., van Veldhuisen D.J., Suter T.M., Sleijfer D.T., Perik P.J., 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: A clue to uncover the mechanisms of trastuzumab-related cardiotoxicity, 10.1016/j.ejca.2007.06.024
  34. Ewer Steven M, Ewer Michael S, Cardiotoxicity Profile of Trastuzumab : , 10.2165/00002018-200831060-00002
  35. Russell Stuart D., Blackwell Kimberly L., Lawrence Julia, Pippen John E., Roe Matthew T., Wood Freda, Paton Virginia, Holmgren Eric, Mahaffey Kenneth W., Independent Adjudication of Symptomatic Heart Failure With the Use of Doxorubicin and Cyclophosphamide Followed by Trastuzumab Adjuvant Therapy: A Combined Review of Cardiac Data From the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 Clinical Trials, 10.1200/jco.2009.23.6950
  36. Perez Edith A., Koehler Maria, Byrne Julie, Preston Alaknanda J., Rappold Erica, Ewer Michael S., Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials, 10.1016/s0025-6196(11)60896-3
  37. Gressett Sarah M, Shah Sachin R, Intricacies of Bevacizumab-Induced Toxicities and Their Management, 10.1345/aph.1l426
  38. Lenihan Daniel J., Tyrosine Kinase Inhibitors: Can Promising New Therapy Associated With Cardiac Toxicity Strengthen the Concept of Teamwork?, 10.1200/jco.2008.18.5439
  39. Schmidinger Manuela, Zielinski Christoph C., Vogl Ursula M., Bojic Andja, Bojic Marija, Schukro Christoph, Ruhsam Marquerite, Hejna Michael, Schmidinger Herwig, Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma, 10.1200/jco.2007.15.6331
  40. Cheng H., Force T., Molecular Mechanisms of Cardiovascular Toxicity of Targeted Cancer Therapeutics, 10.1161/circresaha.109.206920
  41. Chu Tammy F, Rupnick Maria A, Kerkela Risto, Dallabrida Susan M, Zurakowski David, Nguyen Lisa, Woulfe Kathleen, Pravda Elke, Cassiola Flavia, Desai Jayesh, George Suzanne, Harris David M, Ismail Nesreen S, Chen Jey-Hsin, Schoen Frederick J, Van den Abbeele Annick D, Demetri George D, Force Thomas, Chen Ming Hui, Morgan Jeffrey A, Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib, 10.1016/s0140-6736(07)61865-0
  42. Sherwood Louis M., Parris Edith E., Folkman Judah, Tumor Angiogenesis: Therapeutic Implications, 10.1056/nejm197111182852108
  43. Sano Masanori, Minamino Tohru, Toko Haruhiro, Miyauchi Hideyuki, Orimo Masayuki, Qin Yingjie, Akazawa Hiroshi, Tateno Kaoru, Kayama Yosuke, Harada Mutsuo, Shimizu Ippei, Asahara Takayuki, Hamada Hirofumi, Tomita Shuhei, Molkentin Jeffrey D., Zou Yunzeng, Komuro Issei, p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload, 10.1038/nature05602
  44. May D., Gilon D., Djonov V., Itin A., Lazarus A., Gordon O., Rosenberger C., Keshet E., Transgenic system for conditional induction and rescue of chronic myocardial hibernation provides insights into genomic programs of hibernation, 10.1073/pnas.0707778105
  45. Walsh Kenneth, Shiojima Ichiro, Cardiac growth and angiogenesis coordinated by intertissue interactions, 10.1172/jci34126
  46. Chintalgattu Vishnu, Ai Di, Langley Robert R., Zhang Jianhu, Bankson James A., Shih Tiffany L., Reddy Anilkumar K., Coombes Kevin R., Daher Iyad N., Pati Shibani, Patel Shalin S., Pocius Jennifer S., Taffet George E., Buja L. Maximillian, Entman Mark L., Khakoo Aarif Y., Cardiomyocyte PDGFR-β signaling is an essential component of the mouse cardiac response to load-induced stress, 10.1172/jci39434
  47. Goodwin R., Ding K., Seymour L., LeMaitre A., Arnold A., Shepherd F. A., Dediu M., Ciuleanu T., Fenton D., Zukin M., Walde D., Laberge F., Vincent M., Ellis P. M., Laurie S. A., , Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24, 10.1093/annonc/mdq221
  48. Izzedine Hassane, Massard Christophe, Spano Jean Philippe, Goldwasser François, Khayat David, Soria Jean Charles, VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management, 10.1016/j.ejca.2009.11.001
  49. Peng X., Pentassuglia L., Sawyer D. B., Emerging Anticancer Therapeutic Targets and the Cardiovascular System: Is There Cause for Concern?, 10.1161/circresaha.109.211276
  50. Hirsch Emilio, Braccini Laura, Ciraolo Elisa, Morello Fulvio, Perino Alessia, Twice upon a time: PI3K's secret double life exposed, 10.1016/j.tibs.2009.02.003
  51. McMullen J. R., Shioi T., Zhang L., Tarnavski O., Sherwood M. C., Kang P. M., Izumo S., Phosphoinositide 3-kinase(p110 ) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy, 10.1073/pnas.1934654100
  52. Patrucco Enrico, Notte Antonella, Barberis Laura, Selvetella Giulio, Maffei Angelo, Brancaccio Mara, Marengo Stefano, Russo Giovanni, Azzolino Ornella, Rybalkin Sergei D., Silengo Lorenzo, Altruda Fiorella, Wetzker Reinhard, Wymann Matthias P., Lembo Giuseppe, Hirsch Emilio, PI3Kγ Modulates the Cardiac Response to Chronic Pressure Overload by Distinct Kinase-Dependent and -Independent Effects, 10.1016/j.cell.2004.07.017
  53. Hoeller Daniela, Dikic Ivan, Targeting the ubiquitin system in cancer therapy, 10.1038/nature07960
  54. Nowis Dominika, Mączewski Michał, Mackiewicz Urszula, Kujawa Marek, Ratajska Anna, Wieckowski Mariusz R., Wilczyński Grzegorz M., Malinowska Monika, Bil Jacek, Salwa Paweł, Bugajski Marek, Wójcik Cezary, Siński Maciej, Abramczyk Piotr, Winiarska Magdalena, Dąbrowska-Iwanicka Anna, Duszyński Jerzy, Jakóbisiak Marek, Golab Jakub, Cardiotoxicity of the Anticancer Therapeutic Agent Bortezomib, 10.2353/ajpath.2010.090690
  55. Orciuolo Enrico, Buda Gabriele, Cecconi Nadia, Galimberti Sara, Versari Daniele, Cervetti Giulia, Salvetti Antonio, Petrini Mario, Unexpected cardiotoxicity in haematological bortezomib treated patients, 10.1111/j.1365-2141.2007.06659.x
  56. Rubinsztein David C., The roles of intracellular protein-degradation pathways in neurodegeneration, 10.1038/nature05291
  57. Rothermel B. A., Hill J. A., Autophagy in Load-Induced Heart Disease, 10.1161/circresaha.108.186551
  58. Nishida K, Kyoi S, Yamaguchi O, Sadoshima J, Otsu K, The role of autophagy in the heart, 10.1038/cdd.2008.163
  59. Shah M. H., Cardiotoxicity of Histone Deacetylase Inhibitor Depsipeptide in Patients with Metastatic Neuroendocrine Tumors, 10.1158/1078-0432.ccr-05-2689
  60. Dalen, Cochrane Database Syst Rev, 5, CD005006 (2010)
  61. Hensley Martee L., Hagerty Karen L., Kewalramani Tarun, Green Daniel M., Meropol Neal J., Wasserman Todd H., Cohen Gary I., Emami Bahman, Gradishar William J., Mitchell R. Brian, Thigpen J. Tate, Trotti Andy, von Hoff Daniel, Schuchter Lynn M., American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiation Therapy Protectants, 10.1200/jco.2008.17.2627
  62. Suter Thomas M., Procter Marion, van Veldhuisen Dirk J., Muscholl Michael, Bergh Jonas, Carlomagno Chiara, Perren Timothy, Passalacqua Rodolfo, Bighin Claudia, Klijn Jan G.M., Ageev Fail T., Hitre Erika, Groetz Juergen, Iwata Hiroji, Knap Malgorzata, Gnant Michael, Muehlbauer Susanne, Spence Alison, Gelber Richard D., Piccart-Gebhart Martine J., Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial, 10.1200/jco.2006.09.1611
  63. Jones Stephen, Holmes Frankie Ann, O'Shaughnessy Joyce, Blum Joanne L., Vukelja Svetislava J., McIntyre Kristi J., Pippen John E., Bordelon James H., Kirby Robert L., Sandbach John, Hyman William J., Richards Donald A., Mennel Robert G., Boehm Kristi A., Meyer Wally G., Asmar Lina, Mackey Daniel, Riedel Stefan, Muss Hyman, Savin Michael A., Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735, 10.1200/jco.2008.18.4028
  64. Cardinale D., Colombo A., Sandri M. T., Lamantia G., Colombo N., Civelli M., Martinelli G., Veglia F., Fiorentini C., Cipolla C. M., Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition, 10.1161/circulationaha.106.635144
  65. Force, Nat Rev Drug Disc
  66. Bantscheff Marcus, Eberhard Dirk, Abraham Yann, Bastuck Sonja, Boesche Markus, Hobson Scott, Mathieson Toby, Perrin Jessica, Raida Manfred, Rau Christina, Reader Valérie, Sweetman Gavain, Bauer Andreas, Bouwmeester Tewis, Hopf Carsten, Kruse Ulrich, Neubauer Gitte, Ramsden Nigel, Rick Jens, Kuster Bernhard, Drewes Gerard, Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors, 10.1038/nbt1328
  67. Hansen A., Eder A., Bonstrup M., Flato M., Mewe M., Schaaf S., Aksehirlioglu B., Schworer A., Uebeler J., Eschenhagen T., Development of a Drug Screening Platform Based on Engineered Heart Tissue, 10.1161/circresaha.109.211458